NASDAQ:RARXRa Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ra Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $47.99 0.00 (0.00 %) (As of 04/2/2020) Add Compare Share Today's Range$47.99Now: $47.99▼$47.9950-Day Range$47.99MA: $47.99▼$48.0052-Week Range$19.64Now: $47.99▼$48.02Volume30,200 shsAverage Volume1.16 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/ABeta1.05 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingRa Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 10 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.00, Ra Pharmaceuticals has a potential upside of 0.0% from its current price of $47.99.Amount of Analyst CoverageRa Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesRa Pharmaceuticals has received 236 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRa Pharmaceuticals has received 264 “underperform” votes. (Add your “underperform” vote.)Community SentimentRa Pharmaceuticals has received 52.80% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote “Outperform” if you believe RARX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRa Pharmaceuticals does not currently pay a dividend.Dividend GrowthRa Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ra Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Ra Pharmaceuticals is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ra Pharmaceuticals are expected to decrease in the coming year, from ($1.59) to ($3.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ra Pharmaceuticals is -20.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ra Pharmaceuticals is -20.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRa Pharmaceuticals has a P/B Ratio of 8.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.68 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARX Previous Symbol CUSIPN/A CIK1481512 Webwww.rapharma.com Phone617-401-4060Debt Debt-to-Equity Ratio0.01 Current Ratio14.78 Quick Ratio14.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3 million Price / Sales757.11 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book8.63Profitability EPS (Most Recent Fiscal Year)($2.31) Net Income$-102,690,000.00 Net MarginsN/A Return on Equity-44.61% Return on Assets-41.60%Miscellaneous Employees72 Outstanding Shares47,329,000Market Cap$2.27 billion Next Earnings DateN/A OptionableOptionable Receive RARX News and Ratings via Email Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter. Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Ra Pharmaceuticals? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 10 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Ra Pharmaceuticals. How were Ra Pharmaceuticals' earnings last quarter? Ra Pharmaceuticals Inc (NASDAQ:RARX) issued its earnings results on Thursday, February, 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.16. View Ra Pharmaceuticals' earnings history. What price target have analysts set for RARX? 10 Wall Street analysts have issued 12 month target prices for Ra Pharmaceuticals' stock. Their forecasts range from $48.00 to $48.00. On average, they expect Ra Pharmaceuticals' stock price to reach $48.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price. View analysts' price targets for Ra Pharmaceuticals. Has Ra Pharmaceuticals been receiving favorable news coverage? News stories about RARX stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ra Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Ra Pharmaceuticals. Who are some of Ra Pharmaceuticals' key competitors? Some companies that are related to Ra Pharmaceuticals include Elanco Animal Health (ELAN), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Mylan (MYL), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), Zai Lab (ZLAB) and Mirati Therapeutics (MRTX). View all competitors. What other stocks do shareholders of Ra Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Gilead Sciences (GILD), Galmed Pharmaceuticals (GLMD), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sorrento Therapeutics (SRNE), Verastem (VSTM) and Zynerba Pharmaceuticals (ZYNE). Who are Ra Pharmaceuticals' key executives? Ra Pharmaceuticals' management team includes the following people: Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)Mr. David C. Lubner, Exec. VP & CFO (Age 55)Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of ResearchDr. Simon Read, Chief Scientific Officer (Age 48) When did Ra Pharmaceuticals IPO? (RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager. What is Ra Pharmaceuticals' stock symbol? Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX." What is Ra Pharmaceuticals' stock price today? One share of RARX stock can currently be purchased for approximately $47.99. How big of a company is Ra Pharmaceuticals? Ra Pharmaceuticals has a market capitalization of $2.27 billion and generates $3 million in revenue each year. The company earns $-102,690,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe. What is Ra Pharmaceuticals' official website? The official website for Ra Pharmaceuticals is www.rapharma.com. How can I contact Ra Pharmaceuticals? Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
